PedAM
Pediatric Disease Annotations & Medicines
| Disease | down syndrome |
| Phenotype | C0023448|lymphoblastic leukemia |
| Sentences | 5 |
| PubMedID- 22072402 | Previous cytogenetic studies of myeloid and acute lymphoblastic leukemias in children with down syndrome (ml-ds and ds-all) have revealed significant differences in abnormality patterns between such cases and acute leukemias in general. |
| PubMedID- 24222333 | Acute lymphoblastic leukemia in children with down syndrome: a retrospective analysis from the ponte di legno study group. |
| PubMedID- 20418240 | Methotrexate clearance was 5% lower in the acute lymphoblastic leukemia patients with down syndrome (p=0.001); however, this small difference is probably clinically not relevant, because no significant differences in methotrexate plasma levels were detected at 24 and 48 hours. |
| PubMedID- 24391118 | Outcome of transplantation for acute lymphoblastic leukemia in children with down syndrome. |
| PubMedID- 21926964 | Additional activated forms of jak2 include oncogenic fusions, such as pcm1-jak2 as a consequence of a recurrent t(8;9)(p21;p24) or point mutations at sites different from v617, such as the r683g mutation in down syndrome children with b-progenitor acute lymphoblastic leukemias (b-all), additional jak2 point mutations in pediatric or adult b-all and others 29-32. further, oncogenic cytokine receptors, including crlf2 in b-all can lead to constitutive jak2 signaling 32. there may be substantial overlap in jak2 signaling and analogous mutations in the jak2 kinase domain would be predicted to cause drug resistance similar to the results observed in our study. |
Page: 1